Pathogen inactivation of cellular blood products-An additional safety layer in transfusion medicine

Frontiers in Medicine

Volumn 4, Issue DEC, 2017, Pages

  Seltsam, Axel ^a  

^a Institute Springe   (Germany)

Author keywords

Pathogen inactivation; Platelets; Red blood cells; Transfusion; Ultraviolet light

Indexed keywords

EID: 85061835969     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2017.00219     Document Type: Short Survey

References (36)

1. Engelfriet CP, Reesink HW, Snyder EL, Dzik WH, Masse M, Naegelen C, et al. The official requirements for platelet concentrates. Vox Sang (1998) 75(4):308-17. doi:10.1046/j.1423-0410.1998.75403081.x
2. Devine DV, Bradley AJ, Maurer E, Levin E, Chahal S, Serrano K, et al. Effects of prestorage white cell reduction on platelet aggregate formation and the activation state of platelets and plasma enzyme systems. Transfusion (1999) 39(7):724-34. doi:10.1046/j.1537-2995.1999.39070724.x
3. Harrington T, Kuehnert MJ, Kamel H, Lanciotti RS, Hand S, Currier M, et al. West Nile virus infection transmitted by blood transfusion. Transfusion (2003) 43(8):1018-22. doi:10.1046/j.1537-2995.2003.00481.x
4. Bianco C. Dengue and chikungunya viruses in blood donations: risks to the blood supply? Transfusion (2008) 48(7):1279-81. doi:10.1111/j.1537-2995.2008.01806.x
5. Lanteri MC, Kleinman SH, Glynn SA, Musso D, Keith Hoots W, Custer BS, et al. Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications. Transfusion (2016) 56(7):1907-14. doi:10.1111/trf.13677
6. Motta IJ, Spencer BR, Cordeiro da Silva SG, Arruda MB, Dobbin JA, Gonzaga YB, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med (2016) 375(11):1101-3. doi:10.1056/NEJMc1607262
7. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion (2007) 47(12):2338-47. doi:10.1111/j.1537-2995.2007.01512.x
8. Pereira A. Methylene-blue-photoinactivated plasma and its contribution to blood safety. Transfusion (2004) 44(6):948-50; author reply 950. doi:10.1111/j.0041-1132.2004.359_6.x
9. Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol (2006) 19(1):205-42. doi:10.1016/j.beha.2005.04.001
10. Seltsam A, Muller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol (2013) 162(4):442-54. doi:10.1111/bjh.12403
11. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother (2011) 38(1):19-31. doi:10.1159/000323937
12. Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother (2011) 38(1):8-18. doi:10.1159/000324160
13. Seltsam A, Muller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother (2011) 38(1):43-54. doi:10.1159/000323845
14. Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother (2011) 38(1):33-42. doi:10.1159/000324458
15. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood (2004) 104(5):1534-41. doi:10.1182/blood-2003-12-4443
16. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood (2003) 101(6):2426-33. doi:10.1182/blood-2002-03-0932
17. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol (2010) 150(2):209-17. doi:10.1111/j.1365-2141.2010.08227.x
18. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion (2010) 50(11):2362-75. doi:10.1111/j.1537-2995.2010.02694.x
19. Rebulla P, Vaglio S, Beccaria F, Bonfichi M, Carella A, Chiurazzi F, et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion (2017) 57(5):1171-83. doi:10.1111/trf.14042
20. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion (2011) 51(3):622-9. doi:10.1111/j.1537-2995.2010.02873.x
21. Gelderman MP, Chi X, Zhi L, Vostal JG. Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion. Transfusion (2011) 51(11):2343-57. doi:10.1111/j.1537-2995.2011.03135.x
22. Corash L, Lin JS, Sherman CD, Eiden J. Determination of acute lung injury after repeated platelet transfusions. Blood (2011) 117(3):1014-20. doi:10.1182/blood-2010-06-293399
23. Ypma PF, van der Meer PF, Heddle NM, van Hilten JA, Stijnen T, Middelburg RA, et al. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the pathogen reduction evaluation and predictive analytical rating score (PREPAReS) trial. BMJ Open (2016) 6(1):e010156. doi:10.1136/bmjopen-2015-010156
24. Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion (2005) 45(11):1739-49. doi:10.1111/j.1537-2995.2005.00583.x
25. North AK, Henschler R, Geisen C, Garratty G, Arndt PA, Kattamis A, et al. Evaluation of naturally occurring antibodies to pathogen inactivated red blood cells. Transfusion (2010) 50(Suppl):38A
26. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion. Draft Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (2016)
27. Sachais BS, Paradiso S, Strauss D, Shaz BH. Implications of the US Food and Drug Administration draft guidance for mitigating septic reactions from platelet transfusions. Blood Adv (2017) 1(15):1142-7. doi:10.1182/bloodadvances.2017008334
28. Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de La Reunion. Transfusion (2009) 49(6):1083-91. doi:10.1111/j.1537-2995.2009.02111.x
29. Kuehnert MJ, Epstein JS. Assuring blood safety and availability: Zika virus, the latest emerging infectious disease battlefront. Transfusion (2016) 56(7):1669-72. doi:10.1111/trf.13673
30. Hauser L, Roque-Afonso AM, Beyloune A, Simonet M, Deau Fischer B, Burin des Roziers N, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood (2014) 123(5):796-7. doi:10.1182/blood-2013-09-524348
31. Goodrich RP, Gilmour D, Hovenga N, Keil SD. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion (2009) 49(6):1205-16. doi:10.1111/j.1537-2995.2009.02126.x
32. Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion (2009) 49(12):2612-24. doi:10.1111/j.1537-2995.2009.02334.x
33. Kleinman S, Cameron C, Custer B, Busch M, Katz L, Kralj B, et al. Modeling the risk of an emerging pathogen entering the Canadian blood supply. Transfusion (2010) 50(12):2592-606. doi:10.1111/j.1537-2995.2010.02724.x
34. Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med (2005) 15(5):379-87. doi:10.1111/j.1365-3148.2005.00609.x
35. Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion (2010) 50(11):2461-73. doi:10.1111/j.1537-2995.2010.02704.x
36. McCullough J, Goldfinger D, Gorlin J, Riley WJ, Sandhu H, Stowell C, et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion (2015) 55(10):2312-20. doi:10.1111/trf.13149